India’s Mankind Pharma has agreed to acquire a 70% stake in Belgium-based biotechnology company Armed Cell Therapeutics B.V. (ACTx) for €48 million, approximately ₹511 crore. This investment marks Mankind Pharma’s entry into next-generation chimeric antigen receptor T-cell (CAR-T) cancer therapies. The company said the investment would be made in instalments.
The Mankind Pharma Armed Cell Therapeutics acquisition will give the Indian pharmaceutical company access to experimental cancer treatment research targeting non-Hodgkin lymphoma and small cell lung cancer, supporting its ambition to build a global, innovation-led pharmaceutical business.
Significance of Mankind Pharma Armed Cell Therapeutics Acquisition
The Mankind ACT deal represents a strategic move beyond the company’s established pharmaceutical business, which primarily serves the Indian market. Mankind has previously expanded its portfolio through acquisitions, including Bharat Serums and Vaccines in 2024 and oncology and transplant brands from Panacea Biotec Pharma in 2022.
The latest ACTx acquisition shifts Mankind’s focus further towards developing advanced therapies rather than relying solely on established pharmaceutical products.
“Innovation will be one of the defining growth engines for Mankind over the coming decades,” said Mankind Pharma Chief Operating Officer Arjun Juneja in an official statement.
Juneja said the investment would provide access to differentiated scientific platforms, an experienced leadership team, and opportunities to develop multiple next-generation CAR-T candidates.
Mankind Pharma’s long-term ambition includes making advanced therapies more accessible to patients in India and worldwide.
What Is ACTx’s CAR-T Therapies?
CAR-T therapy uses a patient’s T cells, a type of immune cell, which scientists modify to recognise and attack cancer cells. The approach has transformed treatment for some blood cancers, but patients can experience relapse when modified cells lose effectiveness or cancer cells develop resistance.
ACTx is developing armed CAR-T therapies, which are engineered with additional biological components intended to strengthen and sustain their anti-cancer activity. With the Mankind Pharma Armed Cell Therapeutics acquisition, the company also aims to target multiple cancer markers, potentially making it harder for tumours to escape treatment.
Another research direction involves in vivo CAR-T cell generation, which aims to produce the modified immune cells inside a patient’s body rather than modifying cells outside the body before returning them.
These ACTx CAR-T therapy approaches remain under development, and their potential benefits require further scientific and clinical evaluation.
What Is ACTx’s Cancer Research Pipeline?
Armed Cell Therapeutics’ lead research programmes focus on two cancers:
- Non-Hodgkin lymphoma: A group of cancers affecting the lymphatic system. ACTx is investigating approaches relevant to the challenge of relapse following existing CAR-T treatments.
- Small cell lung cancer: An aggressive form of lung cancer that remains difficult to treat effectively.
ACTx conducts research and development through teams in the United States and Europe, with its headquarters in Belgium and operations in the Netherlands. Its founders include Paul Stoffels, former chief executive of Galapagos and former chief scientific officer of Johnson & Johnson, and John Mellors, a University of Pittsburgh professor and former Galapagos executive. Peter Verhaeghe, a former chair of Argenx, is also among its founders.
Opportunities and Risks Of The Mankind ACT Deal
The Mankind Pharma Armed Cell Therapeutics acquisition strengthens Mankind Pharma’s presence in biotechnology research and gives it exposure to a developing area of cancer treatment. However, investment in experimental therapies carries significant scientific and commercial risks.
ACTx’s candidates must undergo the necessary testing to establish their safety and effectiveness and will require applicable regulatory approvals before they can reach patients. The investment in 70% stakes does not itself guarantee successful clinical outcomes or future commercialisation.
For Mankind Pharma, the ACTx acquisition represents a longer-term investment in research capabilities, scientific innovation and potential expansion into complex cancer therapies.
